bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.92 USD
+0.01 (1.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.93 +0.01 (0.78%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Company Summary
Cambridge, MA-based bluebird bio, Inc., is focused on developing gene therapies for severe genetic diseases.
In August 2022, the FDA approved betibeglogene autotemcel (beti-cel), under the brand name Zynteglo, as a one-time gene therapy for the treatment of transfusion-dependent β-thalassemia (TDT) in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
In September 2022, bluebird received an accelerated FDA approval for another gene therapy — eli-cel, marketed as Syskona, as a treatment for patients under 18 years of age with cerebral adrenoleukodystrophy (CALD). Both therapies were launched in the fourth ...
Company Summary
Cambridge, MA-based bluebird bio, Inc., is focused on developing gene therapies for severe genetic diseases.
In August 2022, the FDA approved betibeglogene autotemcel (beti-cel), under the brand name Zynteglo, as a one-time gene therapy for the treatment of transfusion-dependent β-thalassemia (TDT) in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
In September 2022, bluebird received an accelerated FDA approval for another gene therapy — eli-cel, marketed as Syskona, as a treatment for patients under 18 years of age with cerebral adrenoleukodystrophy (CALD). Both therapies were launched in the fourth quarter of 2022.
In December 2023, bluebird obtained FDA’s approval for its third gene therapy, lovotibeglogene autotemcel (lovo-cel), for the treatment of sickle cell disease (“SCD”) in patients ages 12 and older who have a history of vaso-occlusive events, under the brand name Lyfgenia. Lyfgenia works by genetically modifying a patient’s blood stem cells to produce HbAT87Q. This gene-therapy-derived hemoglobin functions similarly to hemoglobin A, which is the standard adult hemoglobin produced in people not affected by SCD. Red blood cells containing HbAT87Q have a lower risk of sickling and occluding blood flow. These modified stem cells are then delivered to the patient.
bluebird completed the separation of the oncology business into a separate independent entity, 2seventy bio, Inc., listed on the NASDAQ on Nov 5, 2021. This has allowed the company to focus on the severe genetic disease business.
In January 2023, bluebird announced that it is floating a secondary issue of 20 million shares of its common stock to the public at an issue price of $6.00 per share (excluding underwriting discounts), approximately amounting to $120 million. bluebird also granted an option to the underwriters of the issue to purchase an additional 3 million shares at the same price.
Revenues for 2022 from continued operations were $3.6 million compared to $3.7 million in 2021.
General Information
bluebird bio, Inc
455 GRAND UNION BOULEVARD
SOMERVILLE, MA 02145
Phone: 339-499-9300
Fax: NA
Web: http://www.bluebirdbio.com
Email: investor@bluebirdbio.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.47 |
Current Year EPS Consensus Estimate | -1.72 |
Estimated Long-Term EPS Growth Rate | 38.70 |
Exp Earnings Date | 5/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 0.91 |
52 Week High | 5.53 |
52 Week Low | 0.88 |
Beta | 0.74 |
20 Day Moving Average | 5,239,110.50 |
Target Price Consensus | 4.34 |
4 Week | -27.91 |
12 Week | -3.48 |
YTD | -33.13 |
4 Week | -25.72 |
12 Week | -6.16 |
YTD | -37.46 |
Shares Outstanding (millions) | 109.34 |
Market Capitalization (millions) | 100.89 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 28.26% |
vs. Previous Quarter | 1.49% |
vs. Previous Year | 17,353.52% |
vs. Previous Quarter | 79.85% |
Price/Book | 0.44 |
Price/Cash Flow | NA |
Price / Sales | 4.64 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | -34.32 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | -14.44 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | 1.55 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | 1.42 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | -419.65 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | -419.64 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | -419.50 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | 2.08 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | 2.49 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | 0.00 |